Phaseline

Targets › AXL

AXL (Tyrosine-protein kinase receptor UFO): drug programs, companies and trials

6 programs from 6 companies in 29 trials: 16 Phase 1, 7 Phase 2, 6 Phase 3; Oncology, Respiratory; next expected readout Dec 2026.

Receptor tyrosine kinase that transduces signals from the extracellular matrix into the cytoplasm by binding growth factors GAS6 and PROS1, and which is thus regulating many physiological processes including cell survival, cell proliferation, migration and differentiation. Ligand binding at the cell surface induces dimerization and autophosphorylation of AXL. Following activation by ligand, AXL binds and induces…. (UniProt, P30530)

Open in Phaseline: the race on AXL, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityBemcentinib
Tyrosine-protein kinase receptor UFO inhibitor
AXLPhase 3Head & Neck Squamous Cell CarcinomaMar 2028
Beijing Scitech-Mq PharmaceuticalsST-1898
Receptor tyrosine kinase (RTK) inhibitor targeting VEGFR2, c-MET, AXL, PDGFRA, RET, and KI
VEGFR2, MET, AXL, PDGFRA, RETPhase 2Differentiated Thyroid Carcinoma; Unresectable or Metastatic Melanoma; Advanced Renal Cell CarcinomaDec 2026
Xuanzhu BiopharmaceuticalXZB-0004
AXL receptor tyrosine kinase inhibitor
AXLPhase 1Advanced Solid TumorFeb 2027
Jonsson Comprehensive Cancer CenterAB801
AXL inhibitor
AXLPhase 1Borderline Resectable Pancreatic Ductal AdenocarcinomaJun 2027
QurientAdrixetinib (Q702)
Axl/Mer/CSF1R selective tyrosine kinase inhibitor
AXL, MER, CSF1RPhase 1Esophageal Cancer; Chronic Graft-Versus-Host DiseaseDec 2027
AstellasGilteritinib
Tyrosine-protein kinase receptor FLT3 inhibitor; Tyrosine-protein kinase receptor UFO inhibitor
FLT3, AXLPhase 1Acute Myeloid Leukemia (AML); Non-small Cell Lung Cancer (NSCLC); AML (Acute Myeloid Leukemia); Acute Myeloid Leukemia …Jul 2028

Conditions

Acute Myeloid Leukemia (7) Acute Myeloid Leukemia (AML) (3) Acute Myeloid Leukemia With FLT3/ITD Mutation (2) Differentiated Thyroid Carcinoma (1) Unresectable or Metastatic Melanoma (1) Advanced Renal Cell Carcinoma (1) Borderline Resectable Pancreatic Ductal Adenocarcinoma (1) Non-small Cell Lung Cancer (NSCLC) (1) AML (Acute Myeloid Leukemia) (1) AML, Adult (1) AML (1) AML - Acute Myeloid Leukemia (1)

Modalities

small molecule (4), mixed (2)

Companies

Beijing Scitech-Mq Pharmaceuticals (1) Jonsson Comprehensive Cancer Center (1) Astellas (1) Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University (1) Qurient (1) Xuanzhu Biopharmaceutical (1)

Related targets

VEGFR2 (1) MET (1) PDGFRA (1) RET (1) FLT3 (1) MER (1) CSF1R (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.